| Nivolumab |
PD-1 |
Metastatic melanoma, metastatic non-small cell lung cancer, advanced renal cell carcinoma, metastatic squamous cell carcinoma, metastatic colorectal cancer, hepatocellular carcinoma |
Higher OS, PFS, ORR, CR in combination with cabozantinib |
[53] |
| Pembrolizumab |
PD-1 |
The most widely indicated ICI in the world, with 17 indications in 11 tumor types, including: melanoma, non-small cell lung cancer, head and neck squamous cancer, classical Hodgkin’s lymphoma, uroepithelial cancer, gastric cancer, etc. |
Significant prolongation of PFS, OS in combination with axitinib. OR, CR, PD extension |
[54] |
| Ipilimumab |
CTLA-4 |
Melanoma, renal cell carcinoma, metastatic colorectal cancer |
Higher OS, PFS, ORR, CR in combination with nivolumab |
[55] |
| Avelumab |
PD-L1 |
Metastatic Merkel cell carcinoma, locally advanced or metastatic uroepithelial carcinoma, advanced renal cell carcinoma |
Higher PFS, ORR, CR in combination with axitinib |
[56] |
| Atezolizumab |
PD-1 |
Uroepithelial carcinoma, NSCLC, triple negative breast cancer, small cell lung cancer |
Prolonged PFS with combination bevacizumab treatment |
[57] |
